RBF Capital’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-63,857
Closed -$47.6K 617
2024
Q4
$47.6K Hold
63,857
﹤0.01% 538
2024
Q3
$77.9K Sell
63,857
-2,400
-4% -$3.82K ﹤0.01% 585
2024
Q2
$137K Hold
66,257
0.01% 542
2024
Q1
$242K Hold
66,257
0.01% 492
2023
Q4
$199K Sell
66,257
-3,743
-5% -$7.59K 0.01% 499
2023
Q3
$151K Hold
70,000
0.01% 491
2023
Q2
$392K Hold
70,000
0.02% 392
2023
Q1
$422K Sell
70,000
-7,307
-9% -$50.9K 0.03% 364
2022
Q4
$441K Hold
77,307
0.03% 357
2022
Q3
$419K Hold
77,307
0.04% 357
2022
Q2
$294K Buy
+77,307
New +$288K 0.02% 415

Other funds holding OMGA

RBF Capital's OMGA Position: Q1 2025 in Review

RBF Capital sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q1 2025, closing a stake of 63,857 shares — an estimated $47.6K sold.

RBF Capital first reported a position in OMGA in Q2 2022 and held it in 11 quarters. The position peaked at $441K in Q4 2022. 4 funds tracked by Wall St. Rank hold OMGA as of Q1 2025.

  • RBF Capital reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • RBF Capital sold 63,857 Omega Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $47.6K.
  • RBF Capital first reported a position in Omega Therapeutics, Inc. Common Stock in Q2 2022 and held it in 11 quarters.
  • RBF Capital's Omega Therapeutics, Inc. Common Stock position peaked at $441K in Q4 2022.
  • 4 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q1 2025.

Based on RBF Capital's 13F filing for Q1 2025, filed 15 May 2025.